4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population

After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with consistent and durable treatment burden ...
MedPage Today on MSN

Anti-VEGF Agent Collects Big Win in Trial of Diabetic Retinopathy

More than 60% of tarcocimab-treated patients had reduced severity ...
Ophthalmology Advisor

Anti-VEGF Injection Noncompliance Key To Poor Long-Term Visual Outcomes

High rates of noncompliance or nonpersistence with anti-vascular endothelial growth factor (VEGF) injections in neovascular ...
Le Lézard

REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Me…

REGENXBIO Inc. today announced positive data from long-term follow-up studies of investigational surabgene lomparvovec ...